Bonesupport Holding AB (publ) BONEX

Stockholm | Biotech | Orthobiologics and bone graft substitutes

General analysis — not personal advice.

Signal
HOLD
Sentiment
5/10
Risk
6/10

CMD improves the long-term bull case (larger addressable market and more future clinical data points), but the sharp sell-off and still-high valuation increase volatility risk into upcoming catalysts (CERAMENT V FDA decision and the Q2 report).

This picture changes. Follow Bonesupport Holding AB (publ) free — email when the signal or risk changes + a Sunday weekly brief.

Follow Bonesupport Holding AB (publ) free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Latest news check: 7 Jun 2026
Exchange
Stockholm
Type
Biotech
Sector
Orthobiologics and bone graft substitutes

Price & valuation

Last close
SEK 225
2026-08-11
1 week
+1.3 %
3 months
-6.0 %
12 months
-26.4 %
From 52w high
-29.4 %
From 52w low
+34.1 %

Market sentiment

Near-term sentiment has weakened after the negative CMD share-price reaction, despite positive longer-term signals (larger US opportunity and added pipeline/study milestones).

Why HOLD?

CMD improves the long-term bull case (larger addressable market and more future clinical data points), but the sharp sell-off and still-high valuation increase volatility risk into upcoming catalysts (CERAMENT V FDA decision and the Q2 report). Therefore, HOLD remains appropriate pending confirmation via regulatory outcome and continued growth/margin delivery.
  • Maintain the current position; consider adding only after clearer confirmation from the CERAMENT V FDA decision and/or the Q2 report on sustained growth and margins.
We're already tracking Bonesupport Holding AB (publ) — here are the latest events we've registered

Recent News

  • Since 6 May, Bonesupport held its Capital Markets Day (26 May), raising the estimated US market potential to ~460,000 procedures (from ~380,000) and announcing two multicenter studies in arthroplasty and spine planned to start in 2027 (spine FDA filing no later than 2031). The share fell about 10% on 26 May on high volume. An FDA De Novo decision for CERAMENT V is expected by August 2026, and improved US reimbursement for CERAMENT G is highlighted as a potential catalyst later in the year.

Catalysts

31 Aug 2026 — CERAMENT V FDA De Novo decision expected in August

What Firelda Watch includes for Bonesupport Holding AB (publ)

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — AI roundup of the week's news
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Bonesupport Holding AB (publ) will be delivered in the same format.

Own Bonesupport Holding AB (publ)? Create a free account and follow up to 3 companies — change history, weekly brief, and email when the picture changes. Upgrade to Watch for more slots and same-day alerts.

Follow 3 companies free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Bonesupport Holding AB (publ) BONEX
Bonesupport Holding AB (publ) — this picture changes. Follow free
Follow Bonesupport Holding AB (publ) free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.